The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
touchEXPERT OPINIONS for touchHAEMATOLOGY
Three internationally renowned multiple myeloma experts share insights into the unmet treatment needs for patients with relapsed/refractory multiple myeloma, the rationale for emerging protein degradation and immunomodulation-based therapies, and the latest data and ongoing clinical trials for these investigational agents.
The experts
Prof. Cristina Gasparetto - Duke Cancer Institute, Durham, NC, USA
Prof. Sagar Lonial - Emory University, Atlanta, GA, USA
Prof. Sundar Jagannath - Tisch Cancer Institute, New York, NY, USA
This touchPODCAST is for HCPs…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.